CXCR4/SDF‐1 axis targeting has been demonstrated in several preclinical and clinical studies as a promising therapeutic strategy for metastatic disease in different cancers, including NSCLC [35, 37, 38]. The gene discussed is CXCL12; the disease is metastatic neoplasm.